BMY Stock Analysis — Bristol Myers Squibb
Sector: Healthcare
AI Verdict
BMY trades at 9.2x next year's earnings while analysts expect EPS to jump 81.2%—that's cheap for the growth on offer if its patent-protected drug pipeline delivers as expected.
Competitive Moat
Bristol Myers Squibb holds a defensible position in branded oncology and immunology drugs, supported by a deep patent portfolio and regulatory exclusivity periods that limit generic competition. Its pipeline strength and ability to scale late-stage clinical trials create a barrier for smaller biotech rivals.
Summary
BMY is notable for its extremely low 9.2x forward P/E despite analysts expecting 81.2% EPS growth next year.
Where It Stands
BMY has delivered a 19.23% 1-year return, trades at 16.7x trailing and 9.2x forward earnings (well below the healthcare sector median of 22x), and its RSI of 50.6 signals a neutral setup.
Key Metrics
- RSI: 50.6 — Neutral
- Trailing P/E: 16.7x
- Forward P/E: 9.2x
- PEG Ratio: 0.21
- Earnings Growth: +0.8%
- Revenue Growth: -0.0%
- Market Cap: $118.0B
- Dividend Yield: 0.04%
- 1-Year Return: 19.23%
- 52-Week High: $62.89
- 52-Week Low: $42.52
Analyst Consensus
15 Buy · 19 Hold · 2 Sell (36 analysts)
Bull Case
With forward EPS growth expected at 81.2% and a forward P/E of just 9.2x, the stock is priced cheaply for the growth analysts are forecasting.
Bear Case
If the forward P/E reverts even halfway to the sector median of 22x after a disappointment, the stock could see a sharp derating despite its neutral RSI of 50.6.
Catalyst to Watch
Upcoming clinical trial readouts or major FDA approvals could either validate the 81.2% EPS growth forecast or trigger a reset in expectations.